In the June issue of Network Matters, Harvard Pilgrim communicated that we will no longer require prior authorization for coverage of the colorectal cancer screening test Cologuard for commercial members. This same change also applies to members of Harvard Pilgrim’s StrideSM (HMO) Medicare Advantage plans.

We have removed the following CPT code from the Stride Molecular Diagnostic Management prior authorization policy, as the test is now covered without prior authorization: